pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda recalls·5d ago·3 min read
save

American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass an

Jul 24, 2026·read at fda recalls ↗

Summary Company Announcement Date: July 24, 2026 FDA Publish Date: July 27, 2026 Product Type: Drugs Reason for Announcement: Recall Reason Description Products were found to contain particulate matter Company Name: American Regent, Inc. Brand Name: Brand Name(s) American Regent, Inc. Product Description: Product Description Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Company Announcement July 24, 2026 – Shirley, NY, American Regent, Inc.

is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass and/or paraformaldehyde.Risk Statement: The administration of an injectable product containing particulate matter may result in local irritation or swelling. The particulate matter could travel through and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death.

Patients with underlying cardiovascular or pulmonary compromise may be at increased risk. To date, American Regent, Inc. has not received any reports of adverse events related to this recall.Papaverine is a prescription medication that relaxes smooth muscles and widens blood vessels, primarily used to treat visceral spasms, poor blood circulation, and erectile dysfunction.

Papaverine Hydrochloride Injection, USP, is a clear, colorless pale-yellow solution and is available in a 2 mL single-dose vial containing 30 mg/mLPapaverine Hydrochloride Injection, USP Lot # 25202 was distributed nationwide in the United States beginning September 30, 2025. NDC, lot, expiration date and distribution dates can be found on the table below.Product Description: Papaverine Hydrochloride Injection, USP 60 mg/2 mL Single dose vialNDC: 0517-4002-25Lot#: 25202Expiration Date: 11/30/2026Distribution Dates: 9/30/2025American Regent, Inc. is notifying its distributors and customers by letter and is arranging for return/replacement etc.

of all recalled products.Distributors/retailers/healthcare facilities that have the product which is being recalled should stop using and return to place of purchase or discard the product.Consumers and healthcare professionals with questions regarding this recall can contact American Regent Inc. using the below information. This product is an intravenous injection and is to be used by or under the direction of a physician.

Patients that use this product which is being recalled should stop using them and contact their doctor or health care provider.Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Contact CenterContact InformationArea of SupportAmerican Regent, Inc. Customer ServicePhone: 800-645-1706 (8:00AM-6:00PM EST, Monday – Thursday, 8:00AM-4:00PM EST, Friday)For detailed return/replacement/credit informationAmerican Regent, Inc. PharmacovigilancePhone: 800-734-9236 Email: pv@americanregent.comTo report adverse eventsAmerican Regent, Inc.

Product Quality ComplaintsPhone: 888-354-4855 (9:00AM-5:00PM EST, Monday – Friday) Email: pqc@americanregent.comFor product quality complaintsAmerican Regent, Inc. Medical InformationPhone: 888-354-4855 (9:00AM-5:00PM EST, Monday – Friday) Email: ma@americanregent.comFor medical questionsAdverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.Complete and submit the report Online: www.fda.gov/medwatch/report.htmRegular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.American Regent, Inc.

is committed to the safety of patients who rely on its products and is taking this precautionary action to protect public health. Company Contact Information Consumers: (800) 645-1706 Product Photos

source

Reporting by fda recalls.

read at fda recalls ↗
566 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5d agoSunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matterfda recalls
  • 5d agoBAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTIONfda recalls
  • 5d agoLIDL US Recalls Eridanous Shortbread Cookies with Chocolate Truffle Coating & Apricot Filling due to Undeclared Wheat, Soy, Milk, and Eggsfda recalls
  • 6d agoMidwest Poultry Services. L.P. Recalls Shell Eggs Due to Possible Salmonella Enteritidis Contaminationfda recalls
  • Jul 21PT Organics Limited Recalls Select Pumpkin Tree Peter Rabbit Organics Banana & Strawberry Fruit Puree Pouches Due to the Potential for Soft Plastic to Enter the Finished Productfda recalls